Research Recommendations For AbCellera Biologics Inc. (ABCL): Here is What You Should Know

AbCellera Biologics Inc. (NASDAQ:ABCL) saw a downside of -14.17% to close Friday at $17.20 after subtracting -$2.84 on the day. The 5-day average trading volume is 3,449,720 shares of the company’s common stock. It has gained $21.46 in the past week. An average of 3,882,285 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,700,218.

ABCL’s 1-month performance is 1.59% or $0.27 on its low of $16.76 reached on 10/01/21. The company’s shares have touched a 52-week low of $14.51 and high of $71.91. YTD, ABCL has lost -57.26% or -$23.04. However, the current price is down -76.08%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On Sep 01, 33 days have gone by since the last insider trading activity for AbCellera Biologics Inc. (ABCL). HAMER JOHN (Director) most recently sold 137,351 shares at $16.93 per share on Sep 01. This transaction cost the insider $2,325,352. Director, HAMER JOHN, sold 162,649 shares at a price of $16.95 on Aug 31. Then, on Jun 22, Director Hayden Michael R sold 100,000 shares at a price of $25.50 per share. This transaction amounted to $2,550,000.

Valuation Metrics

The company’s PE ratio for the last five years has touched a high of 167.83 and a low of 22.50. ABCL stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.48 while the price-to-book (PB) in the most recent quarter is 4.83.

AbCellera Biologics Inc.’s quick ratio for the period ended June 29 was 12.40, with the current ratio over the same period at 12.40 meaning that ABCL stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is 80.82%.

Earnings Surprise

For the quarterly period ending June 29 this year, Analysts expected ABCL to announce $0.08 per share in earnings in its latest quarter, but it posted -$0.01, representing a -112.50% surprise. ABCL stock balance sheet for the quarter ending June 29 shows that, with total debt at $34.9 million

Technical Picture

Let’s look briefly at AbCellera Biologics Inc. (ABCL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 31.71% to suggest the stock is trending Neutral, with historical volatility in this time period at 83.59%.

The stock’s 5-day moving average is $19.46, reflecting a -18.68% or -$3.95 change from its current price. ABCL is currently trading -1.99% above its 20-day SMA, -39.12% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +7.30% and -63.40% respectively.

Stochastic %K and %D was 32.34% and 42.09% and the average true range (ATR) pointed at 1.49. The RSI (14) points at 39.54%, while the 14-day stochastic is at 7.41% with the period’s ATR at 1.41. The stock’s 9-day MACD Oscillator is pointing at -1.33 and -1.05 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for AbCellera Biologics Inc. (NASDAQ: ABCL), SVB Leerink launched coverage with an Outperform rating. Analysts offering their rating for ABCL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ABCL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.

What is ABCL’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $25.00 and a high of $55.00, with their median price target at $49.00. Looking at these predictions, the average price target given by analysts is for AbCellera Biologics Inc. (ABCL) stock is $45.40.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam